APA (7th ed.) Citation

K, S., LR, H., XK, Z., P, Y., CA, H., L, K., & AJ, D. (2022). Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1. Cancer prevention research (Philadelphia, Pa.), 15(6), 411. https://doi.org/10.1158/1940-6207.CAPR-22-0204

Chicago Style (17th ed.) Citation

K, Subbaramaiah, Howe LR, Zhou XK, Yang P, Hudis CA, Kopelovich L, and Dannenberg AJ. "Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1." Cancer Prevention Research (Philadelphia, Pa.) 15, no. 6 (2022): 411. https://doi.org/10.1158/1940-6207.CAPR-22-0204.

MLA (9th ed.) Citation

K, Subbaramaiah, et al. "Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1." Cancer Prevention Research (Philadelphia, Pa.), vol. 15, no. 6, 2022, p. 411, https://doi.org/10.1158/1940-6207.CAPR-22-0204.